{
  "docId": "019de070-14f8-7659-9020-5924af9296cd",
  "docSlug": "a0353e82ff2da767329aa025539c408b",
  "documentTitle": "Legend Biotech | IPO Presentation Deck | 42 slides",
  "authorId": "legend-biotech",
  "authorName": "Legend Biotech",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 42,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide uses a structured three-part framework to explain the product's mechanism and development status.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-14f8-7659-9020-5924af9296cd/23",
  "deckHref": "/decks/019de070-14f8-7659-9020-5924af9296cd",
  "deckJsonHref": "/decks/019de070-14f8-7659-9020-5924af9296cd.json",
  "deckAnchorHref": "/decks/019de070-14f8-7659-9020-5924af9296cd#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.715
      },
      "kind": "list",
      "text": "Clinical Development: IND submission 2H 2020; target population relapsed/refractory PTCL and CTCL.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21cf8b44-e043-4cb5-b67a-3cf5929da977",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.44
      },
      "kind": "list",
      "text": "Target: CD4 is surface glycoprotein on TCL; expressed in normal immune cells; anti-CD4 mAb investigated clinically.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d858b15-542a-4160-92a9-ef0ce8e1a495",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.16
      },
      "kind": "list",
      "text": "MoA/ Scientific Rationale: LB1901 targets CD4 antigen; CD8-enriched anti-CD4 CAR-T; 5-year survival 40%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6fc3939-cff2-4beb-8e34-29f1670cd91b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.02,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "1. Hong X, Song Y, et al. 2. d'Amore F, Radford J, et al.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c9cc2e4-0aca-40f8-b504-cdb1aa414d28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.78,
        "x": 0.11,
        "y": 0.05
      },
      "kind": "title",
      "text": "LB1901 – Autologous CAR-T for T-cell Lymphoma",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "750ffec7-f07f-49fa-bd02-d8ccaae53c3f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "200e84c2-8f59-442f-bc96-913512d54f1e",
      "evidence": "Structured categorization of product information into three distinct thematic blocks.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}